{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:13:18Z","timestamp":1740107598140,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP15K19864"],"award-info":[{"award-number":["JP15K19864"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2019,5,9]]},"DOI":"10.1007\/s00592-019-01289-7","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T12:10:44Z","timestamp":1550059844000},"page":"541-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination therapy of an iNKT cell ligand and CD40\u2013CD154 blockade establishes islet allograft acceptance in nonmyeloablative bone marrow transplant recipients"],"prefix":"10.1007","volume":"56","author":[{"given":"Taichi","family":"Kanzawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihito","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Ikemiyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Saiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Okumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"key":"1289_CR1","unstructured":"National Clinical Guideline Centre (UK, 2015) (2015) Type 1 diabetes in adults: diagnosis and management. NICE Guideline No. 17 [online guideline]. https:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0079032\/ . Accessed 6 June 2018"},{"key":"1289_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/dc15-0079","volume":"38","author":"RP Robertson","year":"2015","unstructured":"Robertson RP (2015) Islet transplantation for type 1 diabetes what have we learned from alloislet and autoislet successes? Diabetes Care 38:1030\u20131035","journal-title":"Diabetes Care"},{"key":"1289_CR3","first-page":"a007823","volume":"2","author":"M McCall","year":"2012","unstructured":"McCall M, Shapiro AM (2012) Update on islet transplantation. Cold Spring Harb Perspect Med 2012 2:a007823","journal-title":"Cold Spring Harb Perspect Med 2012"},{"key":"1289_CR4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.2337\/dc12-0063","volume":"35","author":"FB Barton","year":"2012","unstructured":"Barton FB, Rickels MR, Alejandro R et al (2012) Improvement in outcomes of clinical islet transplantation: 1999\u20132010. Diabetes Care 35:1436\u20131445","journal-title":"Diabetes Care"},{"key":"1289_CR5","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1111\/ajt.12469","volume":"13","author":"AM Brooks","year":"2013","unstructured":"Brooks AM, Walker N, Aldibbiat A et al (2013) Attainment of metabolic goals in the integrated UK islet transplant program with locally isolated and transported preparations. Am J Transpl 13:3236\u20133243","journal-title":"Am J Transpl"},{"key":"1289_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2012.08.003","volume":"364","author":"M Bensellam","year":"2012","unstructured":"Bensellam M, Laybutt DR, Jonas JC (2012) The molecular mechanisms of pancreatic \u03b2-cell glucotoxicity: recent findings and future research directions. Mol Cell Endocrinol 364:1\u201327","journal-title":"Mol Cell Endocrinol"},{"key":"1289_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1463-1326.2009.01115.x","volume":"11","author":"C Talchai","year":"2009","unstructured":"Talchai C, Lin HV, Kitamura T, Accili D (2009) Genetic and biochemical pathways of \u03b2-cell failure in type 2 diabetes. Diabetes Obes Metab 11:38\u201345","journal-title":"Diabetes Obes Metab"},{"key":"1289_CR8","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1016\/j.bbagen.2012.10.025","volume":"1830","author":"M Wallace","year":"2013","unstructured":"Wallace M, Whelan H, Brennan L (2013) Metabolomic analysis of pancreatic beta cells following exposure to high glucose. Biochim Biophys Acta 1830:2583\u20132590","journal-title":"Biochim Biophys Acta"},{"key":"1289_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1463-1326.2009.01112.x","volume":"11","author":"JC Jonas","year":"2009","unstructured":"Jonas JC, Bensellam M, Duprez J, Elouil H, Guiot Y, Pascal SM (2009) Glucose regulation of islet stress responses and \u03b2 cell failure in type 2 diabetes. Diabetes Obes Metab 11:65\u201381","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1289_CR10","doi-asserted-by":"publisher","first-page":"e95451","DOI":"10.1371\/journal.pone.0095451","volume":"9","author":"K Kikawa","year":"2014","unstructured":"Kikawa K, Sakano D, Shiraki N et al (2014) Beneficial effect of insulin treatment on islet transplantation outcomes in Akita mice. PLoS One 9(4):e95451","journal-title":"PLoS One"},{"key":"1289_CR11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1600-6143.2007.02041.x","volume":"8","author":"IR Sweet","year":"2008","unstructured":"Sweet IR, Gilbert M, Scott S et al (2008) Glucose-stimulated increment in oxygen consumption rate as a standardized test of human islet quality. Am J Transpl 8:183\u2013192","journal-title":"Am J Transpl"},{"key":"1289_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2337\/diab.45.2.223","volume":"45","author":"FM Matschinsky","year":"1996","unstructured":"Matschinsky FM (1996) Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45:223\u2013241","journal-title":"Diabetes"},{"key":"1289_CR13","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41598-018-19621-6","volume":"8","author":"JM Mathew","year":"2018","unstructured":"Mathew JM, Voss JH, McEwen ST et al (2018) Generation and characterization of alloantigen-specific regulatory T cells for clinical transplant tolerance. Sci Rep 8:1136","journal-title":"Sci Rep"},{"key":"1289_CR14","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2337\/db13-0019","volume":"62","author":"AM Shapiro","year":"2013","unstructured":"Shapiro AM (2013) Immune antibody monitoring predicts outcome in islet transplantation. Diabetes 62:1377\u20131378","journal-title":"Diabetes"},{"key":"1289_CR15","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.2337\/db08-0358","volume":"57","author":"T Jianming","year":"2008","unstructured":"Jianming T, Shunliang Y, Jinquan C et al (2008) Simultaneous islet-kidney transplantation in seven patients of Type 1 diabetes with end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Diabetes 57:2666\u20132671","journal-title":"Diabetes"},{"key":"1289_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00125-013-3109-4","volume":"57","author":"JB Danielle","year":"2014","unstructured":"Danielle JB, Marc W, Carmen W et al (2014) Mesenchymal stromal cells improve transplanted islet survival and islet function in a syngenic mouse model. Diabetologia 57:522\u2013531","journal-title":"Diabetologia"},{"key":"1289_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/ajt.12606","volume":"14","author":"T Hirai","year":"2014","unstructured":"Hirai T, Ishii Y, Ikemiyagi M et al (2014) A novel approach inducing transplant tolerance by activated invariant natural killer T cells with costimulatory blockade. Am J Transpl 14:554\u2013567","journal-title":"Am J Transpl"},{"key":"1289_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/ajt.13493","volume":"16","author":"T Hirai","year":"2016","unstructured":"Hirai T, Ishii R, Miyairi S et al (2016) Clonal deletion established via invariant NKT cell activation and costimulatory blockade requires in vivo expansion of regulatory T cells. Am J Transpl 16:426\u2013439","journal-title":"Am J Transpl"},{"key":"1289_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/eji.201646670","volume":"47","author":"S Miyairi","year":"2017","unstructured":"Miyairi S, Hirai T, Ishii R et al (2017) Donor bone marrow cells are essential for iNKT cell-mediated Foxp3+ Treg cell expansion in a murine model of transplantation tolerance. Eur J Immunol 47:734\u2013742","journal-title":"Eur J Immunol"},{"key":"1289_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ajt.14453","volume":"18","author":"R Ishii","year":"2018","unstructured":"Ishii R, Hirai T, Miyairi S et al (2018) iNKT cell activation plus T-cell transfer establishes complete chimerism in a murine sublethal bone marrow transplant model. Am J Transpl 18:328\u2013340","journal-title":"Am J Transpl"},{"key":"1289_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2017.01.069","volume":"23","author":"YB Chen","year":"2017","unstructured":"Chen YB, Efebera YA, Johnston L et al (2017) Increased Foxp3(+)Helios(+) regulatory T cells and decreased acute graft-versus-host disease after allogeneic bone marrow transplantation in patients receiving sirolimus and RGI-2001, an activator of invariant natural killer T cells. Biol Blood Marrow Transpl 23:625\u2013634","journal-title":"Biol Blood Marrow Transpl"},{"key":"1289_CR22","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.bbmt.2010.11.022","volume":"17","author":"O Duramad","year":"2011","unstructured":"Duramad O, Laysang A, Li J, Ishii Y, Namikawa R (2011) Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transpl 17:1154\u20131168","journal-title":"Biol Blood Marrow Transpl"},{"key":"1289_CR23","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.2337\/db12-1258","volume":"62","author":"P Lorenzo","year":"2013","unstructured":"Lorenzo P, Matthew JE, Paola M et al (2013) Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes 62:1656\u20131664","journal-title":"Diabetes"},{"key":"1289_CR24","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1111\/ajt.13407","volume":"15","author":"AMS Brooks","year":"2015","unstructured":"Brooks AMS, Carter V, Liew A et al (2015) De novo donor-specific HLA antibodies are associated with rapid loss of graft function following islet transplantation in type 1 diabetes. Am J Transpl 15:3239\u20133246","journal-title":"Am J Transpl"},{"key":"1289_CR25","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1097\/01.TP.0000058516.74246.71","volume":"75","author":"H Li","year":"2003","unstructured":"Li H, Inveradi L, Molano RD, Pileggi A, Ricordi C (2003) Nonlethal conditioning for the induction of allogeneic chimerism and tolerance to islet allografts. Transplantation 75:966\u2013970","journal-title":"Transplantation"},{"key":"1289_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/01.tp.0000167724.38038.ae","volume":"80","author":"B Luo","year":"2005","unstructured":"Luo B, Nanji SA, Schur CD, Pawlick RL, Anderson CC, Shapiro AM (2005) Robust tolerance to fully allogeneic islet transplants achieved by chimerism with minimal conditioning. Transplantation 80:370\u2013377","journal-title":"Transplantation"},{"key":"1289_CR27","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1182\/blood-2004-06-2411","volume":"105","author":"Y Liang","year":"2005","unstructured":"Liang Y, Huang T, Zhang C et al (2005) Donor CD8+ T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb. Blood 105:2180\u20132188","journal-title":"Blood"},{"key":"1289_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2337\/db10-0827","volume":"60","author":"J Racine","year":"2011","unstructured":"Racine J, Wang M, Zhang C et al (2011) Induction of mixed chimerism with MHC-mismatched but not matched bone marrow transplants results in thymic deletion of host-type autoreactive T-cells in NOD mice. Diabetes 60:555\u2013564","journal-title":"Diabetes"},{"key":"1289_CR29","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.4049\/jimmunol.1401137","volume":"193","author":"M Wang","year":"2014","unstructured":"Wang M, Racine J, Zhang M et al (2014) MHC-mismatched chimerism is required for induction of transplantation tolerance in autoimmune nonobese diabetic recipients. J Immunol 193:2005\u20132015","journal-title":"J Immunol"},{"key":"1289_CR30","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.4049\/jimmunol.180.8.5177","volume":"180","author":"FNC William","year":"2008","unstructured":"William FNC, Razavy H, Luo B et al (2008) Development of either split tolerance or robust tolerance along with humoral tolerance to donor and third-party alloantigens in nonmyeloablative mixed chimeras. J Immunol 180:5177\u20135186","journal-title":"J Immunol"},{"key":"1289_CR31","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1111\/j.1600-6143.2012.04260.x","volume":"12","author":"DP Al-Adra","year":"2012","unstructured":"Al-Adra DP, Pawlick R, Shapiro AMJ, Anderson CC (2012) Targeting cells causing split tolerance allows fully allogeneic islet survival with minimal conditioning in NOD mixed chimeras. Am J Transpl 12:3235\u20133245","journal-title":"Am J Transpl"},{"key":"1289_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2337\/diabetes.52.1.59","volume":"52","author":"GF Beilhak","year":"2003","unstructured":"Beilhak GF, Scheffold YC, Weissman IL et al (2003) Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 52:59\u201368","journal-title":"Diabetes"},{"key":"1289_CR33","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2337\/diabetes.53.2.376","volume":"53","author":"B Nikolic","year":"2004","unstructured":"Nikolic B, Takeuchi Y, Leykin I, Fudaba Y, Smith RN, Sykes M (2004) Mixed hematopoietic chimerism allow cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes 53:376\u2013383","journal-title":"Diabetes"},{"key":"1289_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/72162","volume":"6","author":"T Kawai","year":"2000","unstructured":"Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6:114","journal-title":"Nat Med"},{"key":"1289_CR35","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/ajt.14197","volume":"17","author":"SC Kim","year":"2017","unstructured":"Kim SC, Wakwe W, Higginbotham LB et al (2017) Fc-Silent anti-CD154 domain antibody effectively prevents nonhuman primate renal allograft rejection. Am J Transpl 17:1182\u20131192","journal-title":"Am J Transpl"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-019-01289-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T16:15:03Z","timestamp":1694621703000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-019-01289-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,9]]}},"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1007\/s00592-019-01289-7","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"type":"print","value":"0940-5429"},{"type":"electronic","value":"1432-5233"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"assertion":[{"value":"14 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y. Ishii is the executive chairman of REGiMMUNE Corp. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Animal studies were approved by the Tokyo Women\u2019s Medical University internal committee on the use and care of laboratory animals approved all experiments (Reference ID: AE16-105-2). All animals received human care according to the criteria outlined in the \u201cGuide for the Care and Use of Laboratory Animals\u201d prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23, revised 1985) as well as the current version of the Japanese law \u201cAct on Welfare and Management of Animals\u201d (revised 2013).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal right disclosure"}},{"value":"For this type of study formal informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}